export const heartfailure = {
  // 1. BASIC INFORMATION
  interventionName: "Cerner Heart Failure Risk Assessment v1.5.7",
  modelName: "Cerner Heart Failure Risk Assessment",
  version: "v1.5.7",
  developerName: "Oracle Cerner Corporation",
  developerContact: "Oracle Cerner Corporation\n2800 Rockcreek Parkway, North Kansas City, MO 64117\nEmail: clinical.ai@cerner.com\nPhone: 1-800-237-6371",
  releaseDate: "March 15, 2024",
  fundingSource: "Oracle Corporation internal R&D funding in collaboration with American Heart Association Heart Failure Research Committee",
  valueOutput: "5-year heart failure development risk percentage with stage classification (Stage A-D) and ejection fraction categorization",
  outputType: "Prediction & Risk Classification",
  
  // 2. PURPOSE OF INTERVENTION
  intendedUse: "Early detection and risk stratification for heart failure development to inform preventive interventions and treatment planning",
  intendedPatientPopulation: "Adults aged 45+ years at risk for heart failure or with early-stage heart failure presenting for cardiac evaluation",
  intendedUsers: "Licensed physicians, nurse practitioners, and physician assistants in cardiology, primary care, and internal medicine practices",
  decisionMakingRole: "Informs & Augments",
  decisionMakingDesc: "Provides clinical decision support to inform and augment clinician judgment; does not replace clinical decision-making",
  
  // 3. CAUTIONED OUT-OF-SCOPE USE
  criticalAvoidances: [
    "Emergency/Acute Settings: Not for use during acute heart failure episodes or emergencies",
    "Pediatric Populations: Not validated for patients under 45 years of age", 
    "End-Stage Heart Failure: Not appropriate for patients with Stage D heart failure or on advanced therapies",
    "Post-Transplant: Not for heart transplant recipients or candidates",
    "Pregnancy: Not validated during pregnancy due to physiological changes",
    "Acute Myocarditis: Not for use during acute inflammatory conditions"
  ],
  knownRisks: [
    "Ejection Fraction Dependency: Performance may vary with borderline EF measurements",
    "Medication Effects: Performance affected by recent medication changes",
    "Comorbidity Complexity: May underestimate risk in patients with multiple comorbidities", 
    "Population Variability: Performance may vary across ethnic and geographic populations",
    "Sole Decision-Making: Never use as the sole basis for treatment decisions",
    "Dynamic Conditions: Performance decreases in rapidly changing clinical conditions"
  ],
  
  // 4. DEVELOPMENT DETAILS AND INPUT FEATURES
  trainingInclusion: "Adults 45+ years; Complete echocardiographic data; Minimum 5-year follow-up; Multi-center cardiac cohorts",
  trainingExclusion: "End-stage heart failure at baseline; Heart transplant recipients; Missing critical cardiac data; Acute myocarditis episodes",
  deifElements: [
    { element: "Race", used: true, usedText: "Yes", description: "White, Black/African American, Hispanic, Asian, Other" },
    { element: "Ethnicity", used: true, usedText: "Yes", description: "Hispanic/Latino, Not Hispanic/Latino" },
    { element: "Sex", used: true, usedText: "Yes", description: "Male, Female (biological sex at birth)" },
    { element: "Date of Birth", used: true, usedText: "Yes", description: "For age calculation (45+ years)" },
    { element: "Language", used: false, usedText: "No", description: "Not included in risk calculation" },
    { element: "Sexual Orientation", used: false, usedText: "No", description: "Not included in risk calculation" },
    { element: "Gender Identity", used: false, usedText: "No", description: "Not included in risk calculation" },
    { element: "Social Determinants", used: true, usedText: "Yes", description: "Insurance status, geographic region, social support" },
    { element: "Health Assessments", used: true, usedText: "Yes", description: "Functional status, medication adherence, lifestyle factors" }
  ],
  demographicRepresentativeness: [
    { variable: "White Race", trainingData: "69.4%", usPopulation: "76.3%", representativeness: "Under-represented" },
    { variable: "Black/African American", trainingData: "26.8%", usPopulation: "13.4%", representativeness: "Over-represented" },
    { variable: "Hispanic/Latino", trainingData: "11.7%", usPopulation: "18.5%", representativeness: "Under-represented" },
    { variable: "Female Sex", trainingData: "48.2%", usPopulation: "50.8%", representativeness: "Good" },
    { variable: "Age 50-70", trainingData: "61.5%", usPopulation: "58.9%", representativeness: "Good" }
  ],
  relevanceToDeployedSetting: "Training data derived from cardiology practices, heart failure clinics, and primary care settings representative of US adult populations at risk for heart failure. Geographic diversity includes urban and rural settings with enhanced representation of high-risk populations.",
  fairnessApproach: "Race/ethnicity-specific thresholds developed with enhanced focus on African American populations who have higher heart failure risk. Separate model calibration for demographic subgroups to ensure equitable performance.",
  biasManagement: "Bi-weekly fairness audits across demographic subgroups. Stratified analysis by race, ethnicity, sex, age, and comorbidity burden. Continuous monitoring for performance disparities with emphasis on health equity.",
  
  // 5. EXTERNAL VALIDATION PROCESS
  externalDataSources: "Framingham Heart Study, Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis Risk in Communities (ARIC) Study, Jackson Heart Study",
  clinicalSettings: "Cardiology clinics, heart failure specialty centers, primary care practices, academic medical centers across 20 US states and 3 international sites",
  externalTestingParty: "Independent validation by American Heart Association Scientific Statements Committee and Heart Failure Society of America Clinical Research Network",
  externalValidationProcess: "Prospective multi-site validation with 5-year follow-up. Discrimination and calibration assessment across heart failure stages and ejection fraction categories. Real-world implementation studies in 10 health systems.",
  externalValidationDemographics: [
    { variable: "White Race", mesa: "58.7%", whi: "81.4%", regards: "67.9%" },
    { variable: "Black Race", mesa: "29.1%", whi: "10.2%", regards: "32.1%" },
    { variable: "Hispanic", mesa: "12.2%", whi: "4.8%", regards: "1.4%" },
    { variable: "Female", mesa: "51.6%", whi: "100%", regards: "54.8%" }
  ],
  externalValidationSampleSizes: {
    mesa: "6,821",
    whi: "8,403", 
    regards: "15,792"
  },
  
  // 6. QUANTITATIVE PERFORMANCE MEASURES
  internalValidationMetrics: {
    aurocValidity: "0.78",
    fairnessScore: "0.75",
    fairnessScoreDesc: "Min subgroup AUROC",
    calibration: "Good",
    calibrationDesc: "Hosmer-Lemeshow p=0.11",
    sensitivity: "74.8%",
    specificity: "72.6%",
    ppv: "11.9%"
  },
  externalValidationMetrics: {
    aurocValidity: "0.74",
    aurocValidityDesc: "External Cohorts",
    fairnessScore: "0.71",
    fairnessScoreDesc: "Min External AUROC",
    calibration: "Good",
    calibrationDesc: "Well-calibrated across sites",
    publishedStudies: "6",
    publishedStudiesDesc: "Published Studies on Heart Failure Prediction"
  },
  outcomeEvaluationReferences: [
    "Kannel WB, et al. 'Profile of heart failure in the Framingham Study: twenty-year follow-up.' Am Heart J. 1991;121(3 Pt 1):951-957.",
    "Butler J, et al. 'Developing therapies for heart failure with preserved ejection fraction: current state and future directions.' JACC Heart Fail. 2014;2(2):97-112.",
    "Ahmad T, et al. 'Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients.' J Am Heart Assoc. 2018;7(8):e008081."
  ],
  realWorldImpact: "Implementation studies show 26% improvement in early heart failure detection and 20% reduction in progression to advanced heart failure when used as clinical decision support.",
  
  // 7. ONGOING MAINTENANCE & MONITORING
  monitoringProcess: "Quarterly performance monitoring using real-world cardiac registry data. Automated alerts when AUROC drops below 0.72 or calibration slope deviates >13% from expected.",
  localDataValidity: "Currently Monitored",
  localDataValidityDesc: "Real-time monitoring across 112 health systems. Average local AUROC: 0.76 (range: 0.71-0.81)",
  fairnessMonitoringProcess: "Monthly stratified analysis by race, ethnicity, sex, age, and ejection fraction. Automated bias detection with enhanced monitoring for African American populations.",
  localFairnessData: "Complete",
  localFairnessDataDesc: "All demographic groups showing consistent performance. Enhanced sensitivity maintained for high-risk populations.",
  updateProcess: "Semi-annual model updates incorporating new heart failure research and guideline changes. Emergency updates triggered if validity drops below threshold. Next major update: Q1 2026 incorporating 2022-2025 cohort data.",
  performanceCorrection: "Immediate deployment halt if AUROC <0.70 or fairness metrics show >18% disparities. Rollback to previous version within 12 hours. Cardiology review within 48 hours.",
  currentMonitoringStatus: [
    "Last Performance Review: July 20, 2025 - Performance stable across all metrics",
    "Known Issues: None currently identified",
    "Pending Updates: Integration of biomarker data (NT-proBNP, troponin) planned for v2.0",
    "Alert Status: No alerts; all systems operating optimally"
  ],
  
  // 8. EVIDENCE BASE & CLINICAL GUIDELINES
  primaryCitation: "Yancy CW, et al. '2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.' Circulation. 2013;128(16):e240-327.",
  supportingGuidelines: [
    "2022 AHA/ACC/HFSA Heart Failure Clinical Practice Guidelines",
    "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", 
    "2019 AHA/ACC Primary Prevention Guidelines for Heart Failure"
  ],
  clinicalEvidenceLevel: "Class I, Level A",
  clinicalEvidenceLevelDesc: "Strong recommendation based on high-quality evidence from multiple large cohort studies",
  
  // 9. TECHNICAL IMPLEMENTATION DETAILS
  algorithmType: "Ensemble Machine Learning Model combining Random Forest and Gradient Boosting with echocardiographic parameter integration",
  integrationMethod: "FHIR R4 Clinical Decision Support Service, HL7 CDS Hooks v1.0, SMART on FHIR v1.0",
  responseTime: "Mean: 698ms, 95th percentile: 1.0s",
  clinicalSupport: "clinical.ai@cerner.com\n1-800-237-6371",
  technicalSupport: "integration.support@cerner.com\nDeveloper Portal: developer.cerner.com",
  regulatoryAffairs: "regulatory@cerner.com",
  
  // FOOTER INFORMATION
  lastUpdated: "July 30, 2025",
  modelCardVersion: "1.5.7",
  documentClassification: "For Healthcare Professional Use Only | HIPAA Compliant | 21st Century Cures Act Compliant"
};